• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[药物治疗与肾功能不全]

[Pharmacotherapy and kidney dysfunction].

作者信息

Keller F

机构信息

Sektion Nephrologie, Universitätsklinikum Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Deutschland.

出版信息

Med Klin Intensivmed Notfmed. 2019 Jun;114(5):444-451. doi: 10.1007/s00063-018-0455-5. Epub 2018 Jul 6.

DOI:10.1007/s00063-018-0455-5
PMID:29980815
Abstract

Essential for drug dose adjustment is the glomerular filtration rate (GFR) not the serum creatinine level. In acute disease, a loading dose must be given that usually corresponds to the normal dose. The eliminated half-life is used to estimate the administration interval. For anti-infective drugs with a concentration-dependent effect, the target is the high peak such as for daptomycin, linezolide, and colistin. For anti-infective drugs with a time-dependent effect, the target is the high trough such as for piperacillin, meropenem and vancomycin. Such drugs with a time-dependent action should best be administered by infusion not by bolus dosing. With continuous renal replacement therapy (CRRT), the total filtration rate corresponds to a GFR of 30-50 ml/min and many antibiotics will not need a dose reduction on CRRT. After intermittent hemodialysis, a new loading dose should be given to ascertain sufficiently high concentrations in the interval until the next dose or next dialysis.

摘要

药物剂量调整的关键是肾小球滤过率(GFR)而非血清肌酐水平。在急性疾病中,必须给予负荷剂量,通常相当于正常剂量。消除半衰期用于估计给药间隔。对于具有浓度依赖性效应的抗感染药物,目标是达到较高的峰值,如达托霉素、利奈唑胺和多粘菌素。对于具有时间依赖性效应的抗感染药物,目标是达到较高的谷值,如哌拉西林、美罗培南和万古霉素。这类具有时间依赖性作用的药物最好通过静脉输注给药,而不是大剂量推注给药。在持续肾脏替代治疗(CRRT)中,总滤过率相当于30 - 50毫升/分钟的GFR,许多抗生素在CRRT时无需减少剂量。在间歇性血液透析后,应给予新的负荷剂量,以确保在下一次给药或下次透析前的间隔期内有足够高的血药浓度。

相似文献

1
[Pharmacotherapy and kidney dysfunction].[药物治疗与肾功能不全]
Med Klin Intensivmed Notfmed. 2019 Jun;114(5):444-451. doi: 10.1007/s00063-018-0455-5. Epub 2018 Jul 6.
2
[Pharmacokinetics and pharmacodynamics in extracorporeal renal replacement therapy].[体外肾脏替代治疗中的药代动力学和药效学]
Med Klin Intensivmed Notfmed. 2021 May;116(4):295-300. doi: 10.1007/s00063-020-00654-7. Epub 2020 Feb 11.
3
The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.肾脏替代治疗方案中的变异性对危重症患者哌拉西林、美罗培南和万古霉素药物清除率的影响:文献分析和剂量方案*。
Crit Care Med. 2014 Jul;42(7):1640-50. doi: 10.1097/CCM.0000000000000317.
4
Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction.肾功能不全癌症患者抗菌药物治疗的药代动力学和药效学考量
World J Nephrol. 2015 Jul 6;4(3):330-44. doi: 10.5527/wjn.v4.i3.330.
5
Poor Correlation between Meropenem and Piperacillin Plasma Concentrations and Delivered Dose of Continuous Renal Replacement Therapy.美罗培南和哌拉西林血浆浓度与持续肾脏替代治疗给药剂量之间的相关性较差。
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02029-20.
6
Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.连续性肾脏替代治疗的危重症患者的抗生素浓度变异性:一项多中心药代动力学研究。
Crit Care Med. 2012 May;40(5):1523-8. doi: 10.1097/CCM.0b013e318241e553.
7
First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.危重症脓毒症患者连续或间断给药时哌拉西林的首剂和稳态群体药代动力学和药效学。
Int J Antimicrob Agents. 2010 Feb;35(2):156-63. doi: 10.1016/j.ijantimicag.2009.10.008. Epub 2009 Dec 16.
8
Estimation of glomerular filtration rate to adjust vancomycin dosage in critically ill patients: superiority of the Chronic Kidney Disease Epidemiology Collaboration equation?估算肾小球滤过率以调整重症患者万古霉素剂量:慢性肾脏病流行病学合作组织方程的优势?
Anaesth Intensive Care. 2014 Mar;42(2):178-84. doi: 10.1177/0310057X1404200203.
9
Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.危重症患者行连续性肾脏替代治疗时哌拉西林他唑巴坦的群体药代动力学:在药代动力学/药效学分析中的应用。
J Antimicrob Chemother. 2014 Jan;69(1):180-9. doi: 10.1093/jac/dkt304. Epub 2013 Aug 1.
10
Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients.哌拉西林和美罗培南的标准剂量在重症监护病房患者中未能达到足够的血浆浓度。
Acta Anaesthesiol Scand. 2016 Nov;60(10):1425-1436. doi: 10.1111/aas.12808. Epub 2016 Sep 21.

引用本文的文献

1
Meropenem Continuous Infusion in a Septic Patient with Periprosthetic Infection and End-Stage Renal Disease Undergoing Prolonged Intermittent Renal Replacement Therapy.美罗培南持续输注用于一名接受长期间歇性肾脏替代治疗的人工关节周围感染合并终末期肾病的脓毒症患者。
Medicina (Kaunas). 2025 Jan 2;61(1):63. doi: 10.3390/medicina61010063.

本文引用的文献

1
[Dose adjustment of anti-infective drugs in patients with renal failure and renal replacement therapy in intensive care medicine : Recommendations from the renal section of the DGIIN, ÖGIAIN and DIVI].[重症医学中肾功能衰竭及肾脏替代治疗患者抗感染药物的剂量调整:德国重症医学与急诊医学跨学科协会、奥地利重症医学协会及德国重症与急诊医学协会肾脏分会的建议]
Med Klin Intensivmed Notfmed. 2018 Jun;113(5):384-392. doi: 10.1007/s00063-018-0416-z. Epub 2018 Mar 15.
2
Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials.长程与短程静脉输注抗假单胞菌β-内酰胺类药物治疗脓毒症患者的随机对照试验的系统评价和荟萃分析。
Lancet Infect Dis. 2018 Jan;18(1):108-120. doi: 10.1016/S1473-3099(17)30615-1. Epub 2017 Nov 5.
3
Liraglutide and Renal Outcomes in Type 2 Diabetes.利拉鲁肽与 2 型糖尿病患者的肾脏结局。
N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.
4
Pharmacokinetic Assessment of Vancomycin Loading Dose in Critically Ill Patients.重症患者万古霉素负荷剂量的药代动力学评估
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00280-17. Print 2017 Aug.
5
Vancomycin-Associated Cast Nephropathy.万古霉素相关性管型肾病
J Am Soc Nephrol. 2017 Jun;28(6):1723-1728. doi: 10.1681/ASN.2016080867. Epub 2017 Jan 12.
6
Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.中度肾功能损害是否会影响复杂性腹腔内感染和复杂性尿路感染的临床结局?两项使用头孢托罗/他唑巴坦的随机对照试验分析。
J Antimicrob Chemother. 2017 Mar 1;72(3):900-905. doi: 10.1093/jac/dkw486.
7
[Therapeutic drug monitoring and individual dosing of antibiotics during sepsis : Modern or just "trendy"?].[脓毒症期间抗生素的治疗药物监测与个体化给药:是现代方法还是仅仅“赶时髦”?]
Med Klin Intensivmed Notfmed. 2018 Mar;113(2):82-93. doi: 10.1007/s00063-016-0213-5. Epub 2016 Sep 13.
8
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.头孢他啶-阿维巴坦联合甲硝唑与美罗培南治疗复杂性腹腔内感染的疗效和安全性:一项随机、对照、双盲、3期研究的结果
Clin Infect Dis. 2016 Jun 1;62(11):1380-1389. doi: 10.1093/cid/ciw133. Epub 2016 Mar 8.
9
Suboptimal antimicrobial drug exposure in patients with renal impairment.肾功能不全患者抗菌药物暴露不足。
Int J Clin Pharm. 2015 Oct;37(5):906-16. doi: 10.1007/s11096-015-0141-0. Epub 2015 May 28.
10
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.卡格列净在2型糖尿病合并3期肾病患者中的疗效和安全性。
Am J Nephrol. 2014;40(1):64-74. doi: 10.1159/000364909. Epub 2014 Jul 17.